Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
21 févr. 2019 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
19 févr. 2019 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Appoints Brian Di Donato as Chief Financial Officer
11 févr. 2019 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
31 janv. 2019 06h00 HE
|
Achillion Pharmaceuticals, Inc.
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition -- Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn.,...
Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
03 janv. 2019 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update
17 déc. 2018 16h02 HE
|
Achillion Pharmaceuticals, Inc.
ACH-4471, First Generation Oral factor D Inhibitor- Proof of Concept Validated in both PNH as Monotherapy and in Combination w/C5 Inhibitor - Proof of Mechanism Validated in C3G, End of Phase 2...
Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
10 déc. 2018 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D...
Achillion Reports Third Quarter 2018 Financial Results
07 nov. 2018 06h00 HE
|
Achillion Pharmaceuticals, Inc.
- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy -- Interim data and strategic update planned for December 17, 2018 –- September 30, 2018 cash & securities...
Achillion to Present at the Leerink Partners Roundtable Series
25 sept. 2018 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will...
Achillion Appoints Paul Firuta Chief Operating Officer
10 sept. 2018 06h00 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and...